Wolverine Stack UK - BPC-157 + TB-500 Evidence Guide
Wolverine Stack UK: BPC-157, TB-500, Scientific Evidence, Testing and UK Law
“Wolverine Stack” is an online marketing nickname usually applied to a combination of BPC-157 and TB-500. It is not a recognised scientific name, a standardised formulation or an authorised medicine. The research record is frequently overstated because studies of BPC-157, full-length thymosin beta-4 and the seven-residue TB-500 fragment are blended together as though they involved the same material.
Direct Answer
The standard online meaning of Wolverine Stack is a blend containing BPC-157 and TB-500. BPC-157 is a synthetic 15-residue peptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. TB-500 is currently understood by FDA and WADA research as the N-terminally acetylated seven-residue thymosin beta-4 fragment Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln.
No robust controlled clinical trial of the exact Wolverine Stack was identified. Most supportive claims rely on BPC-157 experiments in rats or isolated tendon cells, combined with studies of full-length thymosin beta-4. Full-length thymosin beta-4 is a 43-residue protein-like peptide and is not chemically identical to the seven-residue TB-500 fragment.
FDA’s May 2026 TB-500 assessment stated that it found no human data for products containing the defined TB-500 substances and found insufficient nonclinical evidence to support wound-healing effectiveness. FDA also described BPC-157 as insufficiently characterised for safety and effectiveness, with limited human information and potential immunogenicity concerns.
Both components are prohibited in sport under the 2026 World Anti-Doping Agency list. No current UK marketing authorisation for the combined stack, BPC-157 or TB-500 was identified for this article.
Key Points
What Is the Wolverine Stack?
The term usually refers to BPC-157 and TB-500 sold together, either as separate vials or as a co-formulated blend.
“Wolverine Stack” is not a pharmacopoeial name, an International Nonproprietary Name or a recognised research protocol. It is a commercial nickname inspired by a fictional character associated with rapid regeneration. The name does not imply affiliation with any entertainment company.
Different sellers use different quantities and ratios. Some products marketed as “Super Wolverine” add compounds such as KPV or GHK-Cu. This variation shows why the nickname cannot establish chemical identity.
Why the Wolverine Name Can Hide Scientific Differences
The stack combines one clearly defined 15-residue peptide with a second name that has been used inconsistently.
- BPC-157 can be supplied as a free peptide, acetate-associated material or another salt form
- TB-500 is now generally defined as Ac-LKKTETQ, a seven-residue fragment
- Some catalogues incorrectly label full-length 43-residue thymosin beta-4 as TB-500
- Some articles cite full-length thymosin beta-4 research while describing the shorter TB-500 fragment
- Some co-formulated products do not provide component-specific assay results
- A stated total milligram amount may not reveal the amount of each component
The correct scientific question is therefore not simply “does the Wolverine Stack work?” It is first: which exact BPC-157 form and which exact thymosin-related molecule are present?
The Two Components
BPC-157 and TB-500 differ in sequence length, chemical origin, evidence base and analytical requirements.
BPC-157
BPC-157 is a synthetic pentadecapeptide. FDA describes BPC-157 as a common name rather than a formal adopted name and notes that different salts and derivatives have been sold under the same label.
PubChem lists the free-peptide formula as C62H98N16O22. The approximate molecular weight is 1,419.5 g/mol.
TB-500
FDA’s 2026 assessment defines TB-500 free base as the N-terminally acetylated amino-acid 17 to 23 fragment of thymosin beta-4.
The reported free-base formula is C38H68N10O14, with an approximate molecular weight of 889.01 g/mol. TB-500 is not full-length thymosin beta-4.
| Feature | BPC-157 | TB-500 |
|---|---|---|
| Residue count | 15 | 7, plus N-terminal acetylation |
| Sequence | GEPPPGKPADDAGLV | Ac-LKKTETQ |
| Approximate mass | 1,419.5 Da | 889.01 Da |
| Primary evidence | Cell and animal studies, limited human reports | Chemistry, metabolism and limited in vitro research |
| Common evidence error | Animal findings presented as established clinical outcomes | Full thymosin beta-4 findings presented as fragment evidence |
| UK marketing authorisation | None identified | None identified |
The TB-500 Identity Problem
This is the most important scientific issue in any Wolverine Stack article.
Full-length thymosin beta-4 contains 43 amino acids and has a molecular mass close to 4.9 kDa. TB-500 is the much shorter N-acetylated fragment Ac-LKKTETQ, corresponding to residues 17 to 23 of thymosin beta-4.
A WADA-funded Ghent University project identified the active content of a commercial TB-500 product as this acetylated seven-residue fragment. FDA adopted the same defined fragment in its 2026 review.
Many frequently cited wound, corneal, cardiac and dermal studies used full-length thymosin beta-4. Those studies may help explain the parent molecule’s biology, but they cannot establish that the isolated seven-residue fragment reproduces every property of the full molecule.
A 2024 metabolism study added another layer of complexity. It suggested that an Ac-LKKTE metabolite showed greater wound-closure activity in the tested fibroblast system than the parent TB-500 fragment. FDA subsequently concluded that evidence supporting TB-500 itself for wound healing remained insufficient.
Interactive Evidence Mismatch Explorer
Select a molecule or combination to see which evidence genuinely belongs to it.
BPC-157
Rat tendon and ligament models, isolated tendon fibroblasts, gastrointestinal animal models and limited human reports.
Thymosin beta-4
Extensive parent-molecule work involving actin, cell migration, wound models and some regulated development.
TB-500
Defined fragment chemistry, anti-doping metabolism work and limited in vitro activity studies.
Wolverine Stack
No robust controlled trial of the exact co-formulated combination was identified.
BPC-157 evidence
Preclinical studies report effects in selected cell and animal systems. FDA’s 2026 assessment found insufficient clinical safety information and insufficient evidence to establish effectiveness.
BPC-157 Research Relevant to Wolverine Stack Claims
BPC-157 has a larger preclinical publication record than TB-500, but most musculoskeletal evidence remains non-human.
Tendon Fibroblast Migration
A 2011 study from National Yang-Ming University examined rat Achilles-tendon fibroblasts. It reported increased explant outgrowth, cell survival under stress and migration associated with FAK-paxillin signalling.
Growth Hormone Receptor Expression
A later study from the same research group measured increased growth hormone receptor messenger RNA and protein in rat tendon fibroblasts. This was a cell-system endpoint, not a clinical outcome.
Transected Achilles Tendon
University of Zagreb-affiliated researchers studied transected rat Achilles tendons and reported changes in biomechanical and histological healing measurements.
Medial Collateral Ligament
A 2010 rat study reported altered healing outcomes following experimentally transected medial collateral ligaments. Translation beyond that controlled model is unestablished.
FDA’s 2026 Assessment
FDA stated that BPC-157 is not well characterised from a physicochemical perspective and that multiple forms have been marketed under the same common name. The agency found insufficient clinical safety information and insufficient evidence to conclude effectiveness for the nominated use it assessed.
FDA also identified potential immunogenicity concerns associated with peptide aggregation and related impurities. Its briefing document proposed not adding BPC-157 free base or BPC-157 acetate to the 503A Bulks List.
What Full-Length Thymosin Beta-4 Research Shows
This body of work is scientifically important but should not be relabelled as direct TB-500 evidence.
Thymosin beta-4 is a naturally occurring 43-residue peptide that binds actin and participates in cell migration, tissue organisation and repair biology. George Washington University researchers produced influential work on the parent molecule in dermal and other wound models.
A 1999 rat full-thickness wound study reported accelerated wound closure and changes in collagen and angiogenesis-related measurements after full-length thymosin beta-4 exposure. Further rat work examined connective-tissue organisation and scar-related outcomes.
A 2013 rat medial collateral ligament study also investigated full-length thymosin beta-4 and reported histological and mechanical differences. This study did not use the seven-residue TB-500 fragment.
Evidence Transfer Warning
Full-length thymosin beta-4 has 43 residues. TB-500 has seven. A shared sequence region does not make the two molecules interchangeable in pharmacokinetics, stability, distribution, metabolism or biological effect.
What Direct TB-500 Fragment Research Shows
The defined fragment has a much thinner evidence base than the parent thymosin beta-4 molecule.
Identity and Anti-Doping Chemistry
A 2012 analytical paper synthesised and characterised the N-terminally acetylated 17 to 23 fragment of thymosin beta-4 found in a commercial TB-500 product. WADA-supported work then studied metabolism and detection.
Metabolism and In Vitro Wound-Closure Assays
A 2024 study quantified TB-500 and metabolites in laboratory systems and rats. The authors reported that the metabolite Ac-LKKTE showed greater wound-closure activity in their fibroblast assay than the parent fragment.
FDA’s 2026 Conclusion
FDA found no human exposure data for drug products containing TB-500 free base or acetate. It also found no nonclinical toxicity studies sufficient to inform safety and concluded that nonclinical pharmacological evidence was lacking to support wound-healing effectiveness.
FDA identified possible immunogenicity risks from aggregation and peptide-related impurities and proposed not adding either defined TB-500 substance to the 503A Bulks List.
Evidence for the Exact BPC-157 + TB-500 Combination
Combining two separately discussed molecules does not create combination evidence.
No robust randomised controlled trial of a chemically verified BPC-157 plus Ac-LKKTETQ TB-500 formulation was identified in the literature reviewed for this article.
A 2021 retrospective report described 16 people treated for knee pain. Twelve received BPC-157 alone and four received BPC-157 with “TB4”. The study had no placebo group, no randomisation, no blinding, no imaging-confirmed repair endpoint and no clear analytical confirmation that the second peptide was the defined TB-500 fragment.
FDA’s 2026 BPC-157 briefing document also described a spontaneous adverse-event report involving a product labelled BPC-157 plus TB-500. The report described diffuse skin and gingival pigmentation that recurred after re-exposure. A spontaneous report cannot prove causation, but it is relevant to safety surveillance.
Why Mechanistic Complementarity Is Not Proof
It is possible to propose that BPC-157 and a thymosin-related peptide influence different parts of cell migration or repair biology. A plausible mechanism does not establish an effective ratio, compatibility, long-term safety or a clinically meaningful result.
University Research Context in the UK and Elsewhere
University research helps explain repair biology while also showing why direct evidence matters.
University of Glasgow Tendon Research
University of Glasgow researchers studied microRNA-29a and collagen regulation in damaged tendon cells. The university summarised one laboratory finding as:
“Replacement of miR-29a in damaged tendon cells in the laboratory restores collagen production to pre injury levels.”
This is independent tendon-biology research. It is not evidence that the Wolverine Stack produces the same effect.
BPC-157 Animal Models
Zagreb-affiliated groups produced several rat tendon and ligament studies frequently cited in BPC-157 marketing.
Tendon Fibroblast Work
Taiwanese researchers examined rat tendon-cell migration, survival and FAK-paxillin signalling.
Full Thymosin Beta-4
GW researchers developed a substantial parent-molecule research record involving actin, cell migration and wound models.
TB-500 Identification
WADA-funded Ghent University work identified commercial TB-500 as Ac-LKKTETQ and developed metabolism and detection research.
Wolverine Stack Evidence at a Glance
The evidence becomes weaker as the question moves from individual laboratory systems to the exact commercial stack.
| Question | Evidence type | Current conclusion | Main limitation |
|---|---|---|---|
| Is BPC-157 chemically definable? | Sequence databases and analytical chemistry | Yes, when exact form is declared | Different salts and derivatives use the same common name |
| Does BPC-157 affect tendon cells? | Rat-derived fibroblast systems | Selected migration and signalling changes reported | Cell systems do not establish clinical outcomes |
| Does BPC-157 affect animal tendon or ligament models? | Rat studies | Differences reported in selected experiments | Limited independent replication and no direct clinical translation |
| Does full thymosin beta-4 affect wound models? | Cell, animal and parent-molecule research | Biological activity reported | Full thymosin beta-4 is not TB-500 |
| Is TB-500 Ac-LKKTETQ? | Analytical and anti-doping research | Yes, under current FDA and WADA research definitions | Commercial naming remains inconsistent |
| Does TB-500 itself promote wound closure? | Limited in vitro research | Evidence uncertain | A metabolite may account for observed activity |
| Is TB-500 safety established? | FDA 2026 review | No | No human exposure data identified and toxicology gaps remain |
| Is the exact Wolverine Stack clinically validated? | No robust controlled trial identified | No | Nonstandard formulation and inadequate direct evidence |
| Is it authorised in the UK? | Official regulatory sources | No authorisation identified | Classification also depends on claims and presentation |
Important Research Limitations
Several layers of uncertainty are hidden by the simple two-name marketing label.
- The Wolverine Stack is not chemically standardised
- Rat and cell findings dominate the BPC-157 record
- Much thymosin evidence concerns the full 43-residue molecule rather than TB-500
- TB-500 may be metabolised into smaller fragments with different activity
- There is no established optimal blend ratio
- Co-formulation may alter stability, aggregation or assay recovery
- Published studies may not identify the salt form clearly
- Independent replication is limited for many BPC-157 findings
- The exact commercial batch may differ from research material
- No robust controlled trial establishes the stack as a treatment
- Long-term safety of the combination is unknown
- Anecdotes and testimonials cannot replace verified endpoints
How a Wolverine Stack Blend Should Be Tested
A finished blend requires component-specific testing rather than one generic purity result.
Confirm BPC-157
Mass spectrometry should show an ion pattern consistent with the declared BPC-157 form.
Confirm TB-500
The observed mass should match Ac-LKKTETQ rather than full thymosin beta-4.
Tandem MS
Fragment-ion evidence helps distinguish sequence, terminal acetylation and possible derivatives.
Chromatographic Resolution
The method should separate both intended peptides and detectable related substances.
Assay Each Component
Total vial mass cannot establish how much BPC-157 and TB-500 are present separately.
Verify the Blend Proportion
The measured component ratio should be reported with a justified tolerance.
Finished-Vial Consistency
Multiple finished units may need testing to assess component distribution.
Test the Actual Mixture
Separate raw-material stability data do not prove co-formulated stability.
What a Blend-Specific COA Should Include
- Exact BPC-157 chemical form and sequence
- Exact TB-500 sequence, with N-terminal acetylation declared
- Confirmation that TB-500 is not full thymosin beta-4
- Finished-product batch number
- Observed mass for each component
- Component-specific quantitative assay
- Measured BPC-157 to TB-500 ratio
- Raw chromatogram with identifiable peaks
- Related-substance or impurity results
- Counterion information where relevant
- Laboratory identity and report number
- Clear statement of tests not performed
Why “99% Purity” Is Not Enough
A single chromatographic percentage may describe only one peak or one component. It cannot establish both molecular identities, the declared ratio, net quantity, uniformity, aggregation, stability or microbiological quality.
Safety and Product-Quality Concerns
The exact combination lacks a mature safety programme.
BPC-157 Concerns
FDA states that BPC-157 may present immunogenicity risks for certain routes because of aggregation and peptide-related impurities. It also states that available safety information is insufficient to know whether harm could occur.
TB-500 Concerns
FDA found no human exposure data for the defined TB-500 free base or acetate substances. It identified no adequate acute, repeat-dose, genotoxicity, reproductive-toxicity or carcinogenicity programme.
Combination Concerns
A blend introduces additional questions involving compatibility, aggregation, degradation, component ratio and interaction. Safety information about one component cannot automatically define the safety of the mixture.
Spontaneous Adverse Report
FDA’s 2026 BPC-157 briefing document describes a spontaneous report involving a BPC-157 and TB-500 product labelled for research purposes. Diffuse hyperpigmentation and gingival darkening were reported and reportedly recurred after re-exposure. Spontaneous reports cannot prove causation or incidence.
Quality Risks Outside Regulated Manufacture
- Incorrect BPC-157 salt or active moiety
- Full thymosin beta-4 substituted for TB-500 or the reverse
- Incorrect component ratio
- Peptide truncations and deletion sequences
- Oxidation, deamidation or hydrolysis
- Aggregation and possible immune responses
- Incorrect net peptide amount
- Unverified sterility or endotoxin control
- Batch documents that do not match the supplied vial
Wolverine Stack UK Regulatory Position
Regulatory information checked on 21 July 2026.
No Current UK Marketing Authorisation Identified
No current UK marketing authorisation for a BPC-157 plus TB-500 combination, BPC-157 or TB-500 was identified in the official sources reviewed for this article.
The Wolverine Stack should not be presented as an approved UK treatment for wounds, tendon injury, ligament injury, recovery or any other condition.
MHRA Borderline Guidance
MHRA guidance updated on 2 July 2026 explains that classification can consider pharmacological properties, explicit and implied claims, intended purpose, packaging, websites, social-media content and customer reviews.
A “Research Use Only” statement does not settle classification where the wider page uses injury, recovery, treatment, injection or personal-use claims.
Advertising Restrictions
Regulation 279 of the Human Medicines Regulations restricts advertising a medicinal product where the required marketing authorisation, registration or certificate is not in force.
US Regulatory Context
FDA briefing documents published in May 2026 proposed not adding BPC-157 free base, BPC-157 acetate, TB-500 free base or TB-500 acetate to the 503A Bulks List. The advisory discussion was scheduled for 23 July 2026 and should be checked again after the meeting.
WADA and Competitive Sport
Both components are prohibited at all times for athletes subject to the World Anti-Doping Code.
BPC-157 is listed under the non-approved substances category. Thymosin beta-4 and its derivatives, including TB-500, are listed under peptide hormones, growth factors, related substances and mimetics.
The 2026 Prohibited List took effect on 1 January 2026. A research label, supplier statement or lack of medicinal approval does not remove anti-doping consequences.
Common Wolverine Stack Claims Examined
The marketing claims below exceed the direct evidence available for the exact blend.
“The stack is proven to repair tendons.”
BPC-157 and full thymosin beta-4 have been studied in animal tendon or ligament models. No robust trial establishes tendon repair by the exact stack.
“TB-500 has all the effects of thymosin beta-4.”
TB-500 is a seven-residue fragment. Full thymosin beta-4 is a 43-residue molecule with additional active regions.
“The two peptides are clinically synergistic.”
No controlled combination trial was identified. Mechanistic complementarity is not clinical synergy.
“Animal studies prove human recovery benefits.”
Animal injury models can generate hypotheses but do not establish outcomes in people.
“A 1:1 ratio is scientifically optimal.”
No clinically validated ratio was identified. Commercial ratios vary.
“One COA proves the blend is pharmaceutical grade.”
A meaningful blend assessment requires separate identity, quantity, ratio, impurity and stability evidence.
How to Assess Wolverine Stack Evidence Critically
- Does the source define TB-500 as Ac-LKKTETQ?
- Does it distinguish TB-500 from full thymosin beta-4?
- Was the cited study performed on BPC-157, TB-500 or the parent molecule?
- Was the exact combination tested?
- Was the evidence cellular, animal or human?
- Was the experiment independently replicated?
- Was there randomisation, blinding and a control group?
- Were structural repair outcomes measured directly?
- Was the finished blend chemically verified?
- Was each component quantified separately?
- Was the ratio confirmed?
- Were stability and aggregation evaluated?
- Does the COA match the finished batch?
- Are adverse findings presented alongside positive findings?
- Does the source turn parent-molecule evidence into fragment claims?
- Does the page rely on testimonials?
- Is the supplier also the author of the evidence summary?
- Is the claimed use authorised in the UK?
Medical and Editorial Review
This final article has been reviewed for medical context, scientific accuracy, evidence presentation, patient-safety language and editorial clarity by the multidisciplinary panel below.
The reviewers and contributors are identified to provide transparent authorship and accountability. Their inclusion does not represent endorsement of any research product, supplier, personal use, treatment claim or commercial statement discussed in this article.
Dr Laura Geige
Medical Director and Senior Aesthetics Practitioner at It’s Me & You Clinic, with a professional background in dentistry, medical aesthetics and cosmetic dermatology.
Read professional profile
Dr Rimas Geiga
Medical doctor with a professional interest in nutritional sciences, dietology, metabolic health and evidence-based preventative care.
Read professional profile
Dr Snieguole Geige
Dentist and medical doctor with experience across healthcare, preventative medicine and patient-centred clinical standards.
Read professional profile
Dr Giedre Narkiene
Medical doctor and board-certified dermatologist with expertise in medical and cosmetic dermatology, skin health and patient safety.
Read professional profile
Dr Veronika Matutyte
Medical doctor with training and professional experience in gerontology and healthcare management across clinical and hospital settings.
Read professional profile
Livija Samušienė
Qualified cosmetologist with a Bachelor of Health Sciences in cosmetology and a professional interest in skin health, acne and evidence-based aesthetic care.
Read professional profileWolverine Stack UK Frequently Asked Questions
Evidence-led answers about BPC-157, TB-500, blend testing and UK regulation.
What is the Wolverine Stack?
It is an online nickname usually referring to BPC-157 combined with TB-500.
Is Wolverine Stack a scientific name?
No. It is a marketing nickname and does not define a standard formulation.
What is BPC-157?
BPC-157 is a synthetic 15-residue peptide with the sequence GEPPPGKPADDAGLV.
What is TB-500?
Under current FDA and WADA research definitions, TB-500 is the acetylated seven-residue fragment Ac-LKKTETQ.
Is TB-500 the same as thymosin beta-4?
No. Full thymosin beta-4 contains 43 residues, while TB-500 contains seven.
Why are thymosin beta-4 studies cited for TB-500?
TB-500 contains the parent molecule’s actin-binding region, but shared sequence does not establish equivalent behaviour.
Has BPC-157 been studied in tendon cells?
Yes. Rat-derived tendon fibroblast studies measured migration, survival and signalling endpoints.
Has BPC-157 been studied in animal tendons and ligaments?
Yes. Several rat studies reported selected biomechanical and histological differences.
Has TB-500 been studied directly for wound healing?
Direct evidence is limited. FDA concluded in 2026 that evidence was insufficient to support wound-healing effectiveness.
Has the exact Wolverine Stack been tested in a controlled trial?
No robust controlled trial of a chemically verified BPC-157 plus TB-500 blend was identified.
What was the small knee report?
A retrospective 2021 report included 16 people, only four of whom received BPC-157 with a product described as TB4. It had major design and identity limitations.
Does the stack have a proven optimal ratio?
No clinically validated component ratio was identified.
Why can TB-500 COAs be confusing?
Some products and articles confuse the seven-residue fragment with full thymosin beta-4.
What mass should defined TB-500 show?
The reported free-base molecular weight is approximately 889.01 g/mol.
What mass should BPC-157 show?
The free peptide has an approximate molecular weight of 1,419.5 g/mol.
Does 99% HPLC prove a Wolverine Blend is genuine?
No. It does not prove both identities, separate quantities, ratio, uniformity, aggregation or stability.
What should a blend COA include?
It should include exact sequences, chemical forms, component-specific identity and quantity, measured ratio, chromatograms, batch details and test limitations.
What did FDA say about BPC-157 in 2026?
FDA described insufficient clinical safety information, characterisation concerns and inadequate evidence of effectiveness for its reviewed use.
What did FDA say about TB-500 in 2026?
FDA found no human exposure data for the defined substances, major safety-data gaps and insufficient evidence of wound-healing effectiveness.
Is the Wolverine Stack approved in the UK?
No current UK marketing authorisation was identified.
Does Research Use Only settle UK legality?
No. Regulators may consider the complete claims, presentation, intended purpose and pharmacological context.
Is the Wolverine Stack prohibited in sport?
Yes. BPC-157 and thymosin beta-4 derivatives including TB-500 are prohibited under WADA rules.
Key Takeaways
- Wolverine Stack usually means BPC-157 plus TB-500.
- The nickname is not a standardised scientific formulation.
- BPC-157 is a 15-residue peptide, while defined TB-500 is Ac-LKKTETQ.
- TB-500 is not full-length thymosin beta-4.
- Most supportive claims come from BPC-157 animal studies or full thymosin beta-4 research.
- Direct evidence for the exact combination is inadequate.
- FDA’s May 2026 reviews identified substantial characterisation, effectiveness and safety gaps.
- A finished blend requires separate identity, quantity, ratio and stability testing.
- No current UK marketing authorisation was identified.
- Both components are prohibited in competitive sport.
Relevant It’s Me & You Clinic Resources
Read the individual component guides before interpreting any blend claim.
BPC-157 UK
Explore the peptide’s identity, preclinical evidence and testing limitations.
Read the BPC-157 UK guideTB-500 UK
Understand the difference between Ac-LKKTETQ and full thymosin beta-4.
Read the TB-500 UK guideBPC-157 HCl UK
Review how chemical form and naming affect identity and analytical interpretation.
Read the BPC-157 HCl UK guideResearch Peptides UK
Browse the wider series on COAs, testing and UK regulation.
Browse the Research Peptides UK seriesReferences
- PubChem. BPC-157, CID 9941957. PubChem record
- US Food and Drug Administration. BPC-157-related bulk drug substances briefing document. May 2026. FDA briefing document
- US Food and Drug Administration. TB-500-related bulk drug substances briefing document. May 2026. FDA briefing document
- US Food and Drug Administration. Pharmacy Compounding Advisory Committee meeting, 23 to 24 July 2026. FDA meeting page
- Chang CH, Tsai WC, Hsu YH, Pang JH. BPC-157 and tendon fibroblast outgrowth, survival and migration. 2011. PubMed record
- Chang CH, et al. BPC-157 and growth hormone receptor expression in tendon fibroblasts. 2014. PubMed record
- Cerovecki T, et al. BPC-157 in a rat medial collateral ligament model. Journal of Orthopaedic Research. 2010. PubMed record
- Staresinic M, et al. BPC-157 in a rat Achilles tendon model. 2003. PubMed record
- Malinda KM, et al. Thymosin beta-4 and wound healing in a rat full-thickness wound model. 1999. PubMed record
- Xu B, et al. Thymosin beta-4 in a rat medial collateral ligament model. 2013. PubMed record
- Ehrlich HP, et al. Thymosin beta-4, connective-tissue organisation and rat wound repair. 2010. PubMed record
- Esposito S, et al. Synthesis and characterisation of the N-terminal acetylated 17 to 23 fragment of thymosin beta-4 identified in TB-500. 2012. PubMed record
- Simultaneous quantification of TB-500 and its metabolites and in vitro wound-closure screening. 2024. PubMed record
- World Anti-Doping Agency. Investigation of TB-500 metabolism, Ghent University project. WADA research project
- World Anti-Doping Agency. 2026 Prohibited List. WADA resource
- University of Glasgow. Scientific breakthrough unlocks potential novel tendon treatment. 2015. University research summary
- George Washington University Health Sciences Research Commons. Thymosin beta-4 faculty publications. University repository
- Lee E. Intra-articular BPC-157 for knee pain, retrospective report. 2021. PubMed record
- Medicines and Healthcare products Regulatory Agency. Borderline products: how to tell if your product is a medicine. Updated 2 July 2026. MHRA guidance
- Human Medicines Regulations 2012, Regulation 279. Legislation.gov.uk
- International Council for Harmonisation. ICH Q2(R2), Validation of Analytical Procedures. ICH guideline
- UK Accreditation Service. Laboratory accreditation and ISO/IEC 17025 scope. UKAS guidance
